Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 3

1(33.3%)

3Total

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04641416Recruiting

Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps

Role: collaborator

NCT06599424Recruiting

IntraRenal HEmoDynamics to IntegraTE CA-AKI Risk and Monitor NephroprotectiIoN by ImpElla Support.

Role: collaborator

NCT04265040Recruiting

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies

Role: collaborator

NCT04526964Not ApplicableCompleted

Improved Self-management for Patients on Ventricular Assist Device (VAD) Support - Phase 3

Role: collaborator

NCT04366921Unknown

European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO

Role: collaborator

NCT04234230Completed

Improved Self-management for Patients on Ventricular Assist Device (VAD)

Role: collaborator

NCT04095130Completed

Tissue Sodium in Patients With Psoriasis

Role: collaborator

NCT00925834Not ApplicableCompleted

Suggestive Effects on the Diameter of Coronary Arteries

Role: collaborator

NCT00396760Phase 3Unknown

Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery

Role: lead

All 9 trials loaded